brimonidine tartrate · Bausch And Lomb Inc · NDA 208144
Lumify
Earliest generic entry, as listed
14 Jul 2030
Blocked by patent: US 8293742, US 9259425. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8293742 | use U-2222 | 14 Jul 2030 |
| US 9259425 | use U-2222 | 14 Jul 2030 |
| US 11596600 | use U-2222 | 27 Jul 2029 |
| US 11833245 | use U-2222 | 27 Jul 2029 |
| US 12514857 | use U-2222 | 27 Jul 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208144 · 001 · RLD | solution/drops, ophthalmic | 0.025% | 14 Jul 2030 |